IGF::OT::IGF FORMULATION DEVELOPMENT AND EVALUATION STUDIES OF METHOTREXATE, NEVIRAPINE, SUTEZOLID, LEVOFLOXACIN, AND RUXOLITNIB

甲氨蝶呤、奈韦拉平、舒替唑胺、左氧氟沙星和鲁索利尼的 IGF::OT::IGF 制剂开发和评价研究

• 批准号: 8938940
• 负责人: KATHRYN BAUGHMAN
• 金额: $ 12.24万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-13 至 2015-08-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8938940
• 关键词: Acquired Immunodeficiency Syndrome; Antigens; Biological Assay; Biological Availability; Characteristics; Clinical; Clinical Trials; Contracts; Cyclic GMP; Development; Development Plans; Dosage Forms; Drug Delivery Systems; Drug Formulations; Drug Stability; Equipment; Evaluation Studies; Excipients; Goals; Guidelines; HIV; HIV Infections; Immune response; In Vitro; Label; Levaquin; Masks; Methotrexate; National Institute of Allergy and Infectious Disease; Nevirapine; Permeability; Pharmaceutical Preparations; Pharmacologic Substance; Procedures; Property; Records; Reference Standards; Regulation; Research Personnel; Route; Services; Sexual Transmission; Shipping; Ships; Solubility; Taste Perception; United States Dept. of Health and Human Services; United States National Institutes of Health; Validation; absorption; dosage; drug development; improved; manufacturing process; meetings; microbicide; prevent; scale up

The Division of Acquired Immunodeficiency Syndromes (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), maintains a portfolio of contracts to support the development of (1) therapies for HIV infection and its complications and coinfections, and (2) microbicides for preventing the sexual transmission of HIV. Services provided under this contracts assist investigators in academic settings and small pharmaceutical firms in filling specific gaps in their drug development plan as they advance their product towards clinical investigation.

美国国家过敏和传染病研究所 (NIAID)、美国国立卫生研究院 (NIH)、美国卫生与公众服务部 (DHHS) 的获得性免疫缺陷综合症 (DAIDS) 部门维持一系列合同，以支持开发 (1) HIV 感染及其并发症和合并感染的治疗方法，以及 (2) 用于预防性传播艾滋病毒的杀微生物剂。 艾滋病病毒。根据该合同提供的服务可帮助学术机构和小型制药公司的研究人员在将产品推进临床研究时填补其药物开发计划中的特定空白。